Skip to content
Search

Latest Stories

ABPI appoints Jessamy Baird as its Vice President Elect

The Association of the British Pharmaceutical Industry (ABPI) has appointed Jessamy Baird as Vice-President Elect of the ABPI.

Jessamy is Managing Director/Country Lead, Sanofi UK & Ireland. At Sanofi, Jessamy leads the UK organisation to chase the miracles of science to improve people's lives and transform the practice of medicine.


She will join and support ABPI President Elect Susan Rienow, UK Managing Director and Country President of Pfizer, in delivering her presidential priorities and support the ABPI in its mission to make the UK the best place in the world to research, develop and use the medicines and vaccines of the future.

Both Jessamy and Susan will formally take up their new roles on Thursday 25 May.

Jessamy Baird, ABPI Vice-President Elect and Sanofi UK & Ireland’s Managing Director/Country Lead, said: “The pharmaceutical industry is vital to the continued health and wealth of the UK, delivering innovative, life-saving medicines to the NHS and adding £37billon to the UK economy each year. I am proud to have been elected Vice-President by my peers during this crucial period and I look forward to working with the ABPI President to ensure the UK remains a competitive and innovative global life science leader.”

Susan Rienow, ABPI President and UK Managing Director of Pfizer said: “I look forward to working with Jessamy to help the industry navigate the many challenges and opportunities ahead, while always putting patients at the heart of everything we do.

Together, with ABPI colleagues, we will work to improve the commercial environment, ensure patients have access to new medicines, and drive meaningful progress within UK life sciences and beyond towards a more sustainable future.”

Richard Torbett, ABPI Chief Executive said: “We are thrilled to welcome Jessamy into her new role of Vice-President. Together Jessamy and Susan bring a wealth of industry experience and insight. I look forward to working with them both to achieve the ABPI’s shared vision of making the UK the best place in the world to research, develop and use the medicines and vaccines of the future.”

Jessamy began her career in healthcare research/health economics following her BSc. (Hons) in Health Sciences/Health Economics from University of Aberdeen. Since then, she has worked in roles that span the pharmaceutical industry, academia and the NHS.

Jessamy’s prior role within Sanofi was Director of Market Access, UKIE, supporting national and local healthcare access for patients to Sanofi medicines and vaccines. Before joining Sanofi in 2015, she worked at Eli Lilly Ltd in a range of director roles covering Real World Evidence, Market Access strategy and Health Technology Appraisal across Australia, Canada, Europe and Japan.

Jessamy has held Non-Executive/Board level roles in the NHS for more than 10 years, the most recent being Non-Executive Adviser for Hampshire and Isle of Wight Partnership, North Hants CCG, previously a Non-Executive Director at the Isle of Wight Healthcare NHS Trust, and also worked as Executive Director on the Trust Board of an NHS Foundation Trust providing mental health and community care across Hampshire.

More For You

Pharmacist handing medicine to patient, NHS prescription cost freeze debate

Prescription charge will remain at £9.90

Pic credit: iStock

NPA calls for end to prescription charge after freeze announcement

The National Pharmacy Association (NPA) has asked for prescription charges to be completely removed despite the government announcing today that the charge will be frozen for the first time in three years.

Patients will continue paying £9.90 to collect their medication from a pharmacy.

Keep ReadingShow less
RPS launches new prescribing development programme for pharmacists

From 2026, every newly qualified pharmacist will be an independent prescriber

gettyimages

RPS unveils new training programme to enhance pharmacists’ prescribing skills

The Royal Pharmaceutical Society (RPS) has announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

The initiative comes ahead of the NHS mandate that every newly qualified pharmacist will be an independent prescriber by 2026 — a change set to transform the future of pharmacy practice.

Keep ReadingShow less
Varenicline promotes nicotine vaping cessation in young people

Researchers warn that e-cigarette use can increase risk for nicotine addiction,uptake of combusted tobacco and other substance use.

gettyimages

Anti-smoking pill varenicline may help young people quit vaping, new study suggests

Varenicline — a daily pill already offered through NHS Stop Smoking Services — could also support young people in quitting vaping, new research has suggested.

The medication, proven to be more effective than nicotine replacement gums or patches for smoking cessation, was shown to significantly boost vaping abstinence when combined with behavioural counselling in adolescents and young adults.

Keep ReadingShow less
Relying on blue inhalers alone can worsen asthma symptoms, warns MHRA

Patients are advised to use their preventer inhaler regularly, even if their asthma feels under control.

Pic credit: gettyimages

Overuse of blue inhalers can increase risk of severe asthma attacks, warns MHRA

The Medicines and Healthcare products Regulatory Agency (MHRA) is reminding asthma patients to use their preventer (anti-inflammatory) inhalers regularly as prescribed, rather than relying solely on their blue inhalers, also referred to as reliever inhalers.

“Without regular use of a preventer inhaler, symptoms could worsen and increase the risk of severe asthma attacks,” the MHRA warned.

Keep ReadingShow less
13 pharmacists achieve RPS core advanced credential with record pass rate

The latest successful cohort includes pharmacists from both England and Scotland.

Pic credit: Getty Images

13 more pharmacists achieve RPS core advanced credential - Highest pass rate yet

The Royal Pharmaceutical Society (RPS) has announced that 13 more pharmacists have successfully completed Core Advanced Credentialling as part of the latest assessment cohort —achieving a remarkable 93% pass rate, the highest to date.

This brings the total number of pharmacists awarded the RPS core advanced credential to 113 since the launch of the Core Advanced Curriculum in 2023, with successful candidates from GP, secondary care and community settings.

Keep ReadingShow less